Abstract: Disclosed herein are isolated polypeptides or polypeptide complexes that comprise a tumor-associated calcium signal transducer 2 (TROP2) binding domain that has been optimized for binding and kinetic properties. In some embodiments, the isolated polypeptides or polypeptide complexes further comprise a CD3 binding domain.

Abstract: The invention relates to antigen-binding molecules that specifically bind to MHC Class I DLA-12 antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine MHC Class I DLA-12 antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.

Abstract: The present disclosure relates to a composition capable of diagnosing cancer, specifically pancreatic cancer or the like, a diagnostic kit comprising the same, and a method of providing information for diagnosis using the composition. Also, the present disclosure relates to a pharmaceutical composition capable of preventing or treating pancreatic cancer.

Abstract: Provided are an antibody targeting BCMA, a bispecific antibody targeting BCMA and CD3, and applications thereof. The antibody targeting BCMA comprises two heavy chain variable regions, the heavy chain variable regions comprising HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequences of SEQ ID NO: 22, SEQ ID NO: 33 and SEQ ID NO: 42, or HCDR1, HCDR2, and HCDR3 as shown in the amino acid sequences of SEQ ID NO: 26, SEQ ID NO: 37 and SEQ ID NO: 41. The antibody effectively targets human BCMA and binds to cynomolgus BCMA; the bispecific antibody effectively targets both human BCMA and human CD3, and can bind to cynomolgus BCMA and cynomolgus CD3.

Abstract: The present disclosure provides a fusion protein including an anti-CD3 single domain antibody, an exosomal protein CD63 and an RNA binding protein. The fusion protein of the present disclosure achieves the effect of treating cancer, immunoregulation and activating immune cells through various efficacy experiments.

Abstract: A humanized antibody or antigen binding fragment that binds to the poliovirus receptor (PVR) can be utilized in the preparation of antibody drug conjugates (ADCs) to target nucleic acids, peptides and proteins, drugs and radiopharmaceuticals to cancer cells. These antibodies or antigen binding fragments can also be used for checkpoint blockade. The humanized antibody or antigen binding fragment of this invention can also modulate the PVR-DNAM-1 axis in order to upregulate DNAM 1 (CD226) expression on T cells or NK cells. The antibody or antigen binding fragment that bind to PVR can also be incorporated in CAR-T cells or CAR-NK cells. Bispecific antibodies can also be produced by incorporating the anti-CD155 antibodies or antigen binding fragments to engage T cells or NK cells to fight cancers that express CD155.

Abstract: To allow control over injected genetically engineered cells, it is helpful that the genetically engineered cells express a marker that can be used to detect such cells among a pool of unmodified cells. Some embodiments relate to a marked protein comprising a TCR constant domain and an exogenous amino acid variation that comprises a sequence that is detectable and identifiable within the TCR constant domain. Other embodiments relate to an antibody epitope that is attached to a TCR chain. Both the marked proteins and the antibody epitopes can be used to track genetically engineered cells.

Abstract: In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an agent that modulates an N6-methyladenosine (m6A) regulator.

Abstract: Aspects of the disclosure relate to a method of treating glioblastoma in a subject comprising administering to the subject a KDM6B inhibitor. In some aspects, the methods are performed in combination with an immunotherapy. Further aspects relate to a composition comprising a KDM6B inhibitor and an immunotherapy.

Abstract: The present invention relates to the branches of Biotechnology and Medicine. It describes the use of therapeutic compositions comprising a compound that blocks epidermal growth factor and an antibody that blocks the PD-1/PD-1 ligand signaling pathway in the treatment of tumors of epithelial origin, particularly those that express the native form for human KRAS protein. In patients with cancer of epithelial origin expressing native KRAS treated with said therapeutic compositions, an increase in their survival was observed.

Abstract: The present disclosure provides molecules which modulate cell growth. These molecules include those that bind carbohydrates and may find application in the treatment and/or prevention of cell proliferation and/or differentiation disorders, cancer and/or it's migration and/or spread.

Abstract: The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.

Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Abstract: The present disclosure provides methods and kits for diagnosing and assessing SAGE1-positive disorders, and compositions and methods for treating SAGE1-positive disorders. The present disclosure further provides SAGE1 complexes and methods and composition for inhibiting SAGE1 complexes and treating SAGE1-positive disorders.

Abstract: The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Abstract: The invention discloses an application of bacteria in preparation of a synergist for an immune checkpoint inhibitor. The bacteria are active bacteria or inactive whole-cell gut microbiota.

Abstract: Provided herein are, inter alia, antibodies capable of binding Structural Maintenance of Chromosome-1 (SMC1). The antibodies provided herein include novel light chain and heavy chain sequences and bind SMC1 (e.g., SMC1A or SMC1B) with high efficiency and specificity. The SMC1 antibodies provided herein including embodiments thereof may be used for diagnostic and therapeutic purposes, for example, as humanized SMC1 antibodies, antibody drug conjugates or they may form part of bispecific antibodies or chimeric antigen receptors.

Abstract: The present disclosure is directed to a method that involves selecting a subject having a primary tumor and obtaining, from the selected subject, a sample containing exosomes derived from primary tumor cells. The exosomes are isolated from the sample and expression levels of cell migration-inducing and hyaluronan-binding protein (CEMIP) are detected in the isolated exosomes.

Abstract: The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.

Abstract: The invention relates to antigen binding sites, antibodies and fragments thereof, as well as compositions, kits and uses thereof for the treatment, attenuation and/or prevention of human immunodeficiency virus type 1 (HIV-1).